Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review
about
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerTargeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remissionNatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancerClinical application of circulating tumor cells in breast cancer: overview of the current interventional trialsRole of trastuzumab emtansine in the treatment of HER2-positive breast cancerHepatocellular Carcinoma: Basic and Transitional ResearchNovel method for rapid in-situ hybridization of HER2 using non-contact alternating-current electric-field mixing.Trastuzumab emtansine for HER2-positive advanced breast cancer.Cardiac risk in the treatment of breast cancer: assessment and management.HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerCost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsOnline survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancerA Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial ResultsTranslating neoadjuvant therapy into survival benefits: one size does not fit all.Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice.Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunctionPhase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancerTrastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancerLong-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.Measures of outcome in metastatic breast cancer: insights from a real-world scenarioIdentification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growthPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.Melanoma: a model for testing new agents in combination therapies.Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasisAdo-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer.Survival differences among women with de novo stage IV and relapsed breast cancer.Quality Assurance for Patients with Breast Cancer - the Impact of Clinical Cancer Registries.Treating breast cancer in the 21st century: emerging biological therapiesAdo-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potentialMore than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review.Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.
P2860
Q24632855-78BB4C9A-9B73-4458-85D3-AA33392891FBQ26745420-03BD178B-298F-42E9-A951-C8519A3E47C4Q26746081-599342A2-6578-4B29-B8FF-4DE131C7A61FQ26749255-0DF6F625-3715-4208-A54F-AF664DB550BCQ26782856-785A278F-1DA1-44B8-A0E6-FA8A4029FBF9Q26827936-828AC189-3C69-4B93-BFEC-75B6B088E709Q27003258-54FCDB7F-9D93-4E73-80A4-8329ABD8DAE6Q27030563-06A75613-014E-4151-8F9B-4DDF2B7988C7Q27324543-DB102579-2CDD-4C46-8C84-7BA45EFA4871Q27851917-951FBCFE-4BCA-406B-B7E4-C6FCBAE62CF8Q28081385-AC486835-66CE-497E-B616-7AA63B59D142Q28237833-97D37D9F-235B-46F3-8BCD-262C16AB39EAQ28267134-AD06A0DD-B184-4DB3-8FE4-F123020398FBQ28304646-511F17F4-84A4-4D90-A3D0-E8C7974D876FQ28393146-1B3A3A7D-F262-4F84-9163-207FF9074D60Q28547962-31E6BE06-6474-4785-834F-6EF660807D8CQ30251738-B7AA4360-1C9A-48F0-AF97-75BC88C500AEQ30724810-AABD002E-FE59-4F6B-9220-24F49BE6865DQ31039304-68BA41DD-02DE-4C8C-9735-BD905664E700Q33415078-C9F07AFE-ECEC-4F89-B5C0-92A147E5AD91Q33418305-B129DA53-7D5B-4810-85FB-9515FEF0BDE1Q33421995-6EE3FA95-EE32-4793-B3C2-F61DD25E05C8Q33441033-389CE224-6E6B-4962-A34A-71A704AA055DQ33441996-3DE4A9C5-8FE7-4DFB-9CA8-645F030343C2Q33573092-E8ACC03F-C4AD-4048-BCCC-28A807EC7533Q33651550-4FFFC4B8-62EC-4B4F-980A-42C65606355FQ33682910-24451F57-E04C-4792-969E-C9BEA270FCC6Q33699649-C334D8DE-A560-4706-952E-492C1267BF54Q33720335-2360D4F5-F26C-41DE-AEF7-0FD7015C1CCDQ33827808-9913AFCC-2E95-4B8B-93C2-8A9AA0670A51Q33858930-CDF7FB59-0A15-4594-9BB5-A99D9D6A3EF7Q33863916-02C4BE5B-F2A9-4476-8247-36E17089C0AEQ33867316-F750FF50-5616-42BE-8B0D-52C6B9D460F9Q33886306-7ED09D63-6994-462C-80E8-DF62534D0B74Q34231099-94E32ADD-D269-49A6-8FE3-7C7F540E71B9Q34243936-0FAE21B2-0029-40A7-BC61-79063F53EFAAQ34326536-EFB32B17-C52E-4691-8632-BB41246D094DQ34389275-B5490648-74B4-43F0-BA46-0C61F1FEB1D2Q34394390-8E258D03-C99C-42B1-825F-D6C409167F54Q34428153-677798E7-7F2C-4155-9C4F-8333F5FD7740
P2860
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Prognosis of women with metast ...... an institutional-based review
@ast
Prognosis of women with metast ...... an institutional-based review
@en
Prognosis of women with metast ...... an institutional-based review.
@nl
type
label
Prognosis of women with metast ...... an institutional-based review
@ast
Prognosis of women with metast ...... an institutional-based review
@en
Prognosis of women with metast ...... an institutional-based review.
@nl
prefLabel
Prognosis of women with metast ...... an institutional-based review
@ast
Prognosis of women with metast ...... an institutional-based review
@en
Prognosis of women with metast ...... an institutional-based review.
@nl
P2093
P2860
P356
P1476
Prognosis of women with metast ...... an institutional-based review
@en
P2093
Aman U Buzdar
Gabriel N Hortobagyi
Kristine Broglio
Shaheenah Dawood
P2860
P356
10.1200/JCO.2008.19.9844
P407
P577
2009-11-23T00:00:00Z